One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration.
PURPOSE To assess one-year real-world outcomes of faricimab therapy in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF agents and managed using a treat-and-extend (TAE) regimen. METHODS Patients with treatment-resistant nAMD were switched to faricimab. Functional an...